Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DG1ED2
|
|||
| Drug Name |
Pepinemab
|
|||
| Synonyms |
VX15/2503
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Squamous head and neck cell carcinom [ICD-11: 2D60.0; ICD-10: C77.0] | Phase 1/2 | [1] | |
| Company |
Vaccinex
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Semaphorin-4D (SEMA4D) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Axon guidance | |||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Axon guidance mediated by semaphorins | |||
| Reactome | Sema4D mediated inhibition of cell attachment and migration | |||
| Sema4D induced cell migration and growth-cone collapse | ||||
| Other semaphorin interactions | ||||
| WikiPathways | Semaphorin interactions | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04815720) Pepinemab in Combination With Pembrolizumab in Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE B84). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Vaccinex. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.